Richard P. Junghans

Tufts Medical Center — United States

Medicine · Health Sciences

46h-index7.2kcitations181works1.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CAR-T cell therapy research(91), Monoclonal and Polyclonal Antibodies Research(42), Immunotherapy and Immune Responses(40), Immune Cell Function and Interaction(40), T-cell and B-cell Immunology(19)

Publications181 total

Persistence of CMV-specific anti-HIV CAR T cells after adoptive immunotherapy
Journal of Virology·2025· 1 citedOpen Access
Supplemental Figure 3 from Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric Antigen Receptor–Modified T-cell Therapy for CEA<sup>+</sup> Liver Metastases
2023Open Access
Data from Suppression of Human Glioma Xenografts with Second-Generation IL13R-Specific Chimeric Antigen Receptor–Modified T Cells
2023Open Access
Supplemental Figure 1 from Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric Antigen Receptor–Modified T-cell Therapy for CEA<sup>+</sup> Liver Metastases
2023Open Access
Supplementary Figure 1 from Suppression of Human Glioma Xenografts with Second-Generation IL13R-Specific Chimeric Antigen Receptor–Modified T Cells
2023Open Access
Data from Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric Antigen Receptor–Modified T-cell Therapy for CEA<sup>+</sup> Liver Metastases
2023Open Access
Supplemental Figure 3 from Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric Antigen Receptor–Modified T-cell Therapy for CEA<sup>+</sup> Liver Metastases
2023Open Access
Data from Anti-GD3 Chimeric sFv-CD28/T-Cell Receptor ζ Designer T Cells for Treatment of Metastatic Melanoma and Other Neuroectodermal Tumors
2023Open Access
Supplemental Figure 4 from Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric Antigen Receptor–Modified T-cell Therapy for CEA<sup>+</sup> Liver Metastases
2023Open Access
CCR Translation for This Article from Suppression of Human Glioma Xenografts with Second-Generation IL13R-Specific Chimeric Antigen Receptor–Modified T Cells
2023Open Access
Supplemental Figure 2 from Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric Antigen Receptor–Modified T-cell Therapy for CEA<sup>+</sup> Liver Metastases
2023Open Access
Supplementary Data from Second-Generation Anti–Carcinoembryonic Antigen Designer T Cells Resist Activation-Induced Cell Death, Proliferate on Tumor Contact, Secrete Cytokines, and Exhibit Superior Antitumor Activity <i>In vivo</i>: A Preclinical Evaluation
2023Open Access
Supplementary Data from Anti-GD3 Chimeric sFv-CD28/T-Cell Receptor ζ Designer T Cells for Treatment of Metastatic Melanoma and Other Neuroectodermal Tumors
2023Open Access
Data from Second-Generation Anti–Carcinoembryonic Antigen Designer T Cells Resist Activation-Induced Cell Death, Proliferate on Tumor Contact, Secrete Cytokines, and Exhibit Superior Antitumor Activity <i>In vivo</i>: A Preclinical Evaluation
2023Open Access
Supplementary Figure 1 from Suppression of Human Glioma Xenografts with Second-Generation IL13R-Specific Chimeric Antigen Receptor–Modified T Cells
2023Open Access
Supplemental Figure 1 from Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric Antigen Receptor–Modified T-cell Therapy for CEA<sup>+</sup> Liver Metastases
2023Open Access
Data from Anti-GD3 Chimeric sFv-CD28/T-Cell Receptor ζ Designer T Cells for Treatment of Metastatic Melanoma and Other Neuroectodermal Tumors
2023Open Access
Supplementary Data from Anti-GD3 Chimeric sFv-CD28/T-Cell Receptor ζ Designer T Cells for Treatment of Metastatic Melanoma and Other Neuroectodermal Tumors
2023Open Access
Supplementary Data from Second-Generation Anti–Carcinoembryonic Antigen Designer T Cells Resist Activation-Induced Cell Death, Proliferate on Tumor Contact, Secrete Cytokines, and Exhibit Superior Antitumor Activity <i>In vivo</i>: A Preclinical Evaluation
2023Open Access
Data from Suppression of Human Glioma Xenografts with Second-Generation IL13R-Specific Chimeric Antigen Receptor–Modified T Cells
2023Open Access
page 1 of 10Next →

Frequent Co-authors

Steven C. Katz(11), Qiangzhong Ma(11), N. Joseph Espat(10), Prajna Guha(7), Mitchell Thorn(6), Agnes S. Lo(5), Marissa Cunetta(5), Rachel A. Burga(4), Erica M. Gomes(4), Cary Queen(3), Thomas A. Waldmann(3), Gary R. Point(3), Robin Davies(3), Cang T. Nguyen(3), Lauren A. Licata(3), Otto A. Gansow(3), T. A. Waldmann(3), Pieter Telleman(3), William P. Schneider(2), Nicholas F. Landolfi(2)